| KEEP ME UPDATED | TELL A FRIEND | ADD TO MY FAVORITES |
 |
 |
SUGGESTED PRESENTATIONS
 |
Systemic tolerance and autoimmunity A.K. Abbas, USA |
|
Genetics of Autoimmunity M.A. Alarcón-Riquelme, Sweden |
|
The Multiple autoimmune syndromes kaleidoscope J-M. Anaya, Colombia |
|
Persistence of plasma levels of IFN-gamma predicts clinical outcome in human peri-partum
cardiomyopathy A.A. Ansari, USA |
|
Can Glatiramer Acetate affect other autoimmune diseases, in addition to Multiple
Sclerosis R. Arnon, Israel |
|
The state of the art in the serological diagnosis of celiac disease N. Bizzaro, Italy |
|
Long-term follow-up of the antiphospholipid syndrome: Lessons from the “Euro-
Phospholipid project” R. Cervera, Spain |
|
Autoimmune targets of the miRNA pathway E.K.L. Chan, USA |
|
Autoantibody profi les as biomarkers I. Cohen, Israel |
|
Blocking pathogenic antibodies: A new approach to treat auto-immune diseases J.W. Cohen Tervaert, The Netherlands |
|
Autoantibodies in infl ammatory bowel disease K. Conrad, Germany |
|
Vitamin D and autoimmune rheumatic diseases M. Cutolo, Italy |
|
Role of Complement in innate and autoimmunity M. Daha, The Netherlands |
|
TSH receptor antibodies - Receptor regulation and Signal transduction T.F. Davies, USA |
|
Auto-infl ammatory diseases J-M. Dayer, Switzerland |
|
Rethinking Neuropsychiatric Lupus B. Diamond, USA |
|
Autoantibodies in Polymyositis/ Dermatomyositis A. Doria, Italy |
|
New technologies and their application in diagnosis and treatment of autoimmune
disease M.J. Fritzler, Canada |
|
The role of the newly discovered microRNAs in human autoimmune pathology M. Galeazzi, Italy |
|
Epigenetic modulations in the pathogenesis of rheumatoid arthritis S. Gay, Switzerland |
|
Role of regulatory T cells in rheumatic diseases |
|
Recent advances in the treatment of ANCA associated Vasculitis W.L. Gross, Germany |
|
Molecular signaling of apoptosis in naïve and different memory T cell subsets in
aging S. Gupta, USA |
|
The role of Avemar in the treatment of rheumatoid arthritis M. Hidvegi, Hungary |
|
Relevance of long-lived plasma cell for autoimmunity F. Hiepe, Germany |
|
A new BMT method for Stem Cell Disorders S. Ikehara, Japan |
|
HMGB-1: An amplifying mechanism for the development of SLE? J.R. Kalden, Germany |
|
New developments in the Pathogenesis of ANCA-associated C.G.M. Kallenberg, The Netherlands |
|
Management of Antiphospholipid Syndrome M. Khamashta, UK |
|
Pregnancy in APS patients R.A. Levy, Brazil |
|
Dysregulation of B Cells in Autoimmunity P.E. Lipsky, USA |
|
Regulation of infection induced atherosclerosis by alpha/beta T cells and gamma/
delta T cells E. Matsuura, Japan |
|
Redox-Reactive – Autoantibodies J. McIntyre, USA |
|
Inflammation and anti-phospholipid syndrome P.L. Meroni, Italy |
|
Is pulmonary arterial hypertension an autoimmune disease? L. Mouthon, France |
|
Peptide-based therapy in lupus: promising data with a peptide analogue of the
snRNP protein U1-70K S. Muller, France |
|
Control of autoimmune inflammation by CD44-galectin -8 interaction D. Naor, Israel |
|
Autoantibodies in Lymphoma, A. Plaza-López, Spain |
|
Too much TWEAK(ing) may be bad for you: The role of TWEAK-Fn14 interactions in the
pathogenesis of SLE, C. Putterman, USA |
|
Genetics of autoimmune myocarditis, N.R. Rose, USA |
|
The effect of purified micronized flavonoid fraction on prophylactic treatment of
adjuvant arthritis with methotrexate in rats arthritis, J. Rovenský, Slovakia |
|
In vitro study models for Beta2 GPI-phospholipids interactions, B. Rozman, Slovenia |
|
Rituxumab: the preliminary results of the Italian registry for Rituximab in Rheumatoid
Arthritis, P. Sarzi-Puttini, Italy |
|
The history of a Therapeutic Vaccine against Multiple Sclerosis, M. Sela, Israel |
|
Mosaic of Autoimmunity, Y. Shoenfeld, Israel |
|
Anti-C1q antibodies in Lupus Nephritis, R.A. Sinico, Italy |
|
Novel tools and techniques for the diagnosis of autoimmune diseases G. Steiner, Austria |
|
Gene therapy with anti-C5 antibodies in a rat model of antigen induced arthritis
F. Tedesco, Italy |
|
Homemade versus automatization: What is changing in the assays to detect
autoantibodies, A. Tincani, Italy |
|
Interferon induced Thyroiditis: A new autoimmune puzzle Y. Tomer, USA |
|
Targeting T-regulatory cells in autoimmune diseases, E. Toubi, Israel |
|
Antiphospholipid syndrome and toll like receptors, P. Von Landenberg, Germany |
|
The SILISA® - an ELISA for the assessment of side-effects of silicone implants,
G. Wick, Austria |
|
How do we validate new autoantibody tests compared to older ones? A. Wiik, Denmark |
|
Role of Immunoglobulin-like transcripts in autoimmunity, T. Witte, Germany |
|
A novel regulatory T cell subset and the clinical relevance K. Yamamoto, Japan |
|
The interplay between IL-6 and B lymphocytes in autoimmune diseases P. Youinou, France |
| ** | Basic Immunology Course - Registration fee: €100
This half day course is intended to provide an update on selected important issues in basic immunology that are relevant to the understanding of immunological diseases and the development of new therapies. The course will be given Abul K. Abbas, MD, Professor and Chair of the Department of Pathology at the University of California San Francisco. Dr. Abbas is well known for his research in Immunology and as a teacher of the subject. |
| * | XIV NEDAI Annual Meeting Program Round Table: Quality of care and research Autoimmune Diseases Units in the hospitals How can we improve the quality of the Which strategies are effective to promote
|
